2020-2025 Human Papillomavirus (HPV) Testing Industry Report - Roche, Qiagen, Hologic and Abbott are Dominating the Competition

DUBLIN, Feb. 13, 2020 /PRNewswire/ -- The "Human Papillomavirus (HPV) Testing Market - Global Outlook and Forecast 2020 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global HPV testing market is expected to grow at a CAGR of over 12% during the period 2019-2025.

Key Market Insights

• The analysis of the global HPV testing market provides sizing and growth opportunities for the forecast period 2020-2025.
• Offers sizing and growth prospects of the market for the forecast period 2020-2025.
• Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.
• Includes a detailed analysis of growth drivers, challenges, and investment opportunities.
• Delivers a complete overview of segments and the regional outlook of the market.
• Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

The increased procurement of the latest-generation HPV testing analyzers and test kits, coupled with the high prevalence of HPV-related infections and cancers, especially cervical and vaginal, influences the growth of the global HPV testing market. Traditionally, cervical cancer screening was based on cervical cytology. However, in recent years, several countries and global health bodies have recommended the inclusion of HPV tests for cervical and pre-cancer screening programs, which is likely to boost the market.

The demand for new innovative testing consumables and instruments using advanced techniques such as the HPV mRNA test, which promotes accurate and sensitive diagnostic outcomes, is driving the market growth. Further, with the availability of positive clinical evidence, demonstrating the superiority of the latest generation advanced testing devices, end-users will become increasingly aware of clinical benefits and rapidly adopt these tests as an essential screening tool for cervical cancer screening. Therefore, the improvement in patient management, favorable government initiatives for primary screening, and the rising awareness of advanced testing in developed and developing economies are increasing the adoption globally.

Market Segmentation

This research report includes detailed segmentation by products, applications, end-user, and geography.

The consumables segment is growing due to the high adoption of advanced testing kits, reagents, and other related consumables to detect and screen cervical cancers globally. The segment is also growing at a fast rate due to the recurring purchase by end-users to perform HPV tests. These screening tests are likely to gain wide acceptance in emerging economies due to favorable government initiatives and the rise in consumer spending power.

Therefore, market players are focusing on significant product launches in a low resource setting of emerging countries, thereby accelerating the segment growth. The instruments segment is growing at a slow pace as the procurement of analyzers is capital intensive and the purchasing decision depends on financial resources and budget allocations. However, the increasing availability of automated and compact analyzers/instruments has significantly improved the efficiency and quality of end-user operations. Automation and integration of several diagnostic platforms have led to the introduction of innovative diagnostic analyzers, thereby driving the growth during the forecast period.

The cervical application segment is growing on account of the rise in cervical cancer incidences. The increased focus of market players to launch screening products in low resource countries is expected to drive the cervical application segment during the upcoming years. HPV self-sampling is emerging with the rapid availability of these devices as a potential screening strategy, especially in the US, which is likely to contribute to the growth.

The application of HPV testing for vaginal cancer offers powerful negative predictive values. Therefore, the detection of infection with a high-risk HPV, which produce visible signs, is a powerful tool for vaginal cancer screening. Owing to the benefit of HPV testing, coupled with the rise in the vaginal cancer burden globally, vendors are offering innovative testing devices, which are driving the growth of the vaginal application segment.

The increased focus on enhancing the sensitivity of cervical screening to reduce false-negative diagnoses as well as improve the specificity of molecular tests to detect high-risk human papillomavirus is a major factor contributing to the growth of standard reference laboratories. The availability of standard reference laboratory services for the evaluation of HPV DNA and antibody detection in biological specimens through capacity-building worldwide is another reason for the growth of standard reference laboratories.

Healthcare professionals in hospitals use human papillomavirus testing as a screening procedure for the cervical and other related cancers. The market is likely to grow at a fast pace during the forecast period on account of the adoption of advanced testing products. A majority of patients with high-risk symptoms prefer visiting hospitals for diagnosis due to advanced infrastructure facilities available in major private and public hospitals.

The physicians' office and clinic segment is expected to grow mainly on account of the growing prevalence of cervical cancers worldwide. These clinics perform laboratory screening through private offices for people with a high risk of cervical and other HPV associated cancers at an affordable cost. Another factor responsible for the rise of this segment is the availability of super-specialty expertise in these clinics.

Insights by Geography

North America is growing at a significant rate due to the growing preference for HPV tests to detect and screen cervical cancers and other related infections. The presence of a large pool of population with a high risk of developing cervical cancer, the increasing acceptance of HPV testing, and growing awareness of advanced testing procedures have accelerated the market.

Germany, France, the UK, Spain, and Italy are the leading contributors to the Europe market. The presence of highly sophisticated healthcare infrastructure, a high awareness level of advanced HPV screening procedures with high analytic sensitivity for detecting cervical cancers, and increased investment in R&D activities are the major drivers for the growth in the region.

The region has the largest population density and the highest population with a high risk of developing cervical cancers and other associated infections. Japan, China, Australia, South Korea, and India are the major revenue contributors from the region. Japan is the major revenue contributor to the HPV testing market in APAC due to advancements in healthcare infrastructure, the rise in healthcare expenditure, and favorable public and private initiatives for an increase in the healthcare access.

Insights by Vendors

The global HPV testing market is highly competitive and characterized by the presence of several global, regional, and local players. F. Hoffmann-La Roche, QIAGEN, Hologic, and Abbott are the dominant players, and their testing instruments and consumables are widely used by end-users globally.

These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities. Over the years, these players have been dominating the market as they have introduced safe and efficient products in the market.

Vendors, especially global players, are increasingly focusing on pursuing inorganic growth strategies such as acquisitions and strategic partnerships to expand their presence, enhance product portfolio, and improve expertise in the market.

Key Topics Covered

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of the Study
4.4 Market Segments
4.4.1 Market Segmentation by Product
4.4.2 Market Segmentation by Application
4.4.3 Market Segmentation by End-users
4.4.4 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance

7 Introduction
7.1 HPV Infections: An Overview
7.1.1 Background
7.1.2 Types of HPV
7.1.3 Cervical Cancer
7.1.4 HPV Tests
7.1.5 HPV Testing: Market Snapshot

8 Market Dynamics
8.1 Market Growth Enablers
8.1.1 Increasing Prevalence of HPV Infections
8.1.2 Growing Awareness & Favorable Guidelines Endorsing HPV Testing
8.1.3 High Demand for Nucleic Acid Amplification Tests
8.2 Market Growth Restraints
8.2.1 Availability of Alternative Diagnostic Methods for HPV
8.2.2 Increasing Focus on Preventive Measures for HPV Infections
8.2.3 Lower than Expected Market Penetration of HPV Tests
8.3 Market Opportunities and Trends
8.3.1 Emergence of Point-of-care/Rapid HPV Tests
8.3.2 High Growth Potential for HPV Tests in Low Resource Settings of LMICs
8.3.3 Emergence of mRNA Test for Cervical Cancer Screening
8.3.4 Increasing Demand for HPV Co-testing

9 Global HPV Testing Market
9.1 Market Overview
9.2 Market Size & Forecast
9.2.1 By Geography
9.2.2 By Product
9.2.3 By Application
9.2.4 By End-users
9.3 Five Forces Analysis
9.3.1 Threat of New Entrants
9.3.2 Bargaining Power of Suppliers
9.3.3 Bargaining Power of Buyers
9.3.4 Threat of Substitutes
9.3.5 Competitive Rivalry

10 By Products
10.1 Market Snapshot & Growth Engine
10.2 Market Overview
10.3 Consumables
10.4 Instruments

11 By Application
11.1 Market Snapshot & Growth Engine
11.2 Market Overview
11.3 Cervical Cancer
11.4 Vaginal Cancer
11.5 Others

12 By End-Users
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Standard Reference Laboratories
12.4 Hospitals
12.5 Physicians' Offices and Clinics

13 By Geography
13.1 Market Snapshot & Growth Engine
13.2 Overview

14 North America

15 Europe

16 APAC

17 Latin America

18 Middle East & Africa

19 Competitive Landscape
19.1 Competition Overview
19.2 Market Share Analysis
19.2.1 F. Hoffmann-La Roche
19.2.2 QIAGEN
19.2.3 Hologic
19.2.4 Abbott

20 Key Vendors
20.1 F. Hoffmann-La Roche
20.1.1 Business Overview
20.1.2 Major Product Offerings
20.1.3 Key Strengths
20.1.4 Key Strategies
20.1.5 Key Opportunities
20.2 QIAGEN
20.3 Hologic
20.4 Abbott

21 Other Prominent Vendors
21.1 Arbor Vita
21.1.1 Business Overview
21.1.2 Major Product Offerings
21.2 BD
21.3 Cepheid
21.4 DAAN Gene
21.5 DiaCarta
21.6 Fujirebio
21.7 Greiner Bio-One International
21.8 Hybribio
21.9 IncellDx
21.10 Norgen Biotek
21.11 PreTect
21.12 Seegene
21.13 Siemens Healthineers
21.14 Takara Bio
21.15 Xiamen Zeesan Biotech
21.16 Zytovision

For more information about this report visit https://www.researchandmarkets.com/r/ndzz9e

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com